Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.
Eli Lilly could potentially generate $50 billion in annual sales from weight-loss drugs by 2030, positioning the pharmaceutical company as a major beneficiary in the obesity treatment market, according to J.P. Morgan.
Novo Nordisk's stock price rose by over 2% on Wall Street after JPMorgan Chase raised its price target for the company, citing a strong growth profile and potential catalysts such as positive clinical trial data for its weight-loss drug Wegovy.
Crinetics Pharmaceuticals' pill for a growth hormone disorder showed promising results in a study, leading to a 63.3% surge in the biotech stock.
The sale of anti-obesity drugs in Denmark, particularly Ozempic and Wegovy, has significantly boosted the country's economy and prevented it from entering a recession, with the pharmaceutical industry adding almost two percentage points of growth to the GDP in the first half of 2023. The success of these drugs has also made Novo Nordisk, the company behind them, the highest valued company in Europe.
Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.
The global market for weight-loss drugs is projected to reach $100 billion by 2035, with revenue in the US potentially reaching as high as $70 billion alone.
The rise of GLP-1 weight loss drugs like Ozempic and Wegovy has the potential to impact various industries, with drug manufacturers such as Novo Nordisk and Eli Lilly expected to benefit, while medical device companies, fast-food chains, and beer and tobacco companies could be at risk.
Novo Holdings, the controlling shareholder of Novo Nordisk, could receive a significant windfall from the success of weight-loss drug Wegovy, potentially making it a major philanthropist and ESG investor.
The demand for self-injection weight-loss drugs is rising, prompting contract drug manufacturers to invest billions of dollars in expanding or building factories to fill injection pens, as the obesity market could be worth $100 billion within a decade.
Shares of pharmaceutical company Eli Lilly are on the rise, driven by the growth potential of its diabetes and obesity products, leading analysts to predict that it could become the first trillion-dollar bio-pharma company. The company's recent approval of Mounjaro for treating type 2 diabetes has resulted in strong revenue growth, and there is anticipation that it will also gain FDA approval for treating obesity. Wall Street analysts are optimistic about Eli Lilly stock, with a consensus rating of Strong Buy.
Danish drug company experiences stock rise after increasing sales and profit outlook due to high demand for Ozempic and Wegovy in the US.
The growth in demand for appetite suppressing anti-obesity drugs like Novo Nordisk's Wegovy presents opportunities for food manufacturers, and the initial market reaction may be overdone.
JPMorgan analysts predict that emerging weight-loss drugs could create a $100 billion-plus opportunity, with the GLP-1 category expected to exceed $100 billion in annual sales over time, split between diabetes and obesity, and a global market estimate of over $140 billion by 2032.
